TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities.

ABSTRACT: Compared to other breast cancers, triple-negative breast cancer (TNBC) usually affects younger patients, is larger in size, of higher grade and is biologically more aggressive. To date, conventional cytotoxic chemotherapy remains the only available treatment for TNBC because it lacks expression of the estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2), and no alternative targetable molecules have been identified so far. The high biological and clinical heterogeneity adds a further challenge to TNBC management and requires the identification of new biomarkers to improve detection by imaging, thus allowing the specific treatment of each individual TNBC subtype. The Systematic Evolution of Ligands by EXponential enrichment (SELEX) technique holds

SUBMITTER: Camorani S 

PROVIDER: S-EPMC6316260 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature